U.S. Markets closed

Sinovac Biotech Ltd. (SVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.470.00 (0.00%)
At close: 9:43AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.47
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's Range6.47 - 6.47
52 Week Range6.47 - 6.47
VolumeN/A
Avg. Volume0
Market Cap642.437M
Beta (5Y Monthly)0.05
PE Ratio (TTM)6.66
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters

    Botswana pays equivalent of $15 a dose for Sinovac's COVID-19 vaccine

    Botswana's health minister said on Friday that the government was paying the equivalent of $15 a dose for the COVID-19 vaccine developed by China's Sinovac Biotech and almost $29 a dose for U.S. company Moderna's shot. African countries have struggled to procure enough vaccines in the global scramble for doses, with coverage secured through World Health Organization (WHO) and African Union (AU)-backed schemes so far falling short of the continent's needs. Under pressure over a recent spike in COVID-19 infections, health minister Edwin Dikoloti revealed how much the diamond-rich southern African country was paying in bilateral deals with pharmaceutical companies Sinovac, Moderna and India's Bharat Biotech.

  • Reuters

    UPDATE 2-Antibodies from Sinovac's COVID-19 shot fade after about 6 months, booster helps - study

    Antibodies triggered by Sinovac Biotech's COVID-19 vaccine declined below a key threshold from around six months after a second dose for most recipients, but a third shot had a strong booster effect, a lab study showed. Chinese researchers reported the findings from a study of blood samples from healthy adults aged between 18-59 in a paper published on Sunday, which has not been peer reviewed. Among participants who received two doses, two or four weeks apart, only 16.9% and 35.2% respectively still had neutralising antibodies above what researchers regard as a detectable threshold level six months after the second shot, the paper said.

  • Reuters

    UPDATE 1-Brazil says China's Sinopharm seeks COVID-19 vaccine emergency-use authorization

    China National Pharmaceutical Group Co Ltd (Sinopharm) has applied for emergency use authorization for its COVID-19 vaccine in Brazil, the Brazilian health agency Anvisa said in a statement on Monday. Brazil already uses another Chinese COVID-19 vaccine, Sinovac Biotech's Coronavac, which is the vaccine most administered in the South American nation.